Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H17N3O4 |
| Molecular Weight | 303.3132 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)N1C(=O)CC2=CC(=CC=C12)N3C[C@@H](OC3=O)C(N)=O
InChI
InChIKey=FKMDICPKYZOJFW-GFCCVEGCSA-N
InChI=1S/C15H17N3O4/c1-8(2)18-11-4-3-10(5-9(11)6-13(18)19)17-7-12(14(16)20)22-15(17)21/h3-5,8,12H,6-7H2,1-2H3,(H2,16,20)/t12-/m1/s1
| Molecular Formula | C15H17N3O4 |
| Molecular Weight | 303.3132 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:19:58 GMT 2023
by
admin
on
Sat Dec 16 08:19:58 GMT 2023
|
| Record UNII |
7ZX8889BHS
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7ZX8889BHS
Created by
admin on Sat Dec 16 08:19:58 GMT 2023 , Edited by admin on Sat Dec 16 08:19:58 GMT 2023
|
PRIMARY | |||
|
875003-62-6
Created by
admin on Sat Dec 16 08:19:58 GMT 2023 , Edited by admin on Sat Dec 16 08:19:58 GMT 2023
|
PRIMARY | |||
|
11609163
Created by
admin on Sat Dec 16 08:19:58 GMT 2023 , Edited by admin on Sat Dec 16 08:19:58 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
PF-708093 pharmacological activity: Pfizer has discontinued development of PF-708093, an oxazolidinone for the treatment of bacterial infections (Company pipeline, Pfizer, 20 Dec 2006 & 28 Feb 2008, 47th ICAAC, Chicago, 2007)
|
||
|
ACTIVE MOIETY |
Originator: Pfizer; Class: Antibacterial; Mechanism of Action: Undefined mechanism; Highest Development Phase: Discontinued for Bacterial infections; Most Recent Event: 20 Dec 2006 Phase-I clinical trials in Bacterial infections in USA (unspecified route)
|
